Use of fenoldopam to control renal dysfunction early after liver transplantation

Liver Transplantation

Volumn 10, Issue 8, 2004, Pages 986-992

  Biancofiore, Gianni ^a   Della Rocca, Giorgio ^c   Bindi, Lucia ^a   Romanelli, Anna ^d   Esposito, Massimo ^a   Meacci, Luca ^a   Urbani, Lucio ^b   Filipponi, Franco ^b   Mosca, Franco ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; DOPAMINE; FENOLDOPAM MESILATE; FUROSEMIDE; LOOP DIURETIC AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; PLACEBO; PREDNISOLONE; VASOACTIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ANESTHESIA INDUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE CONTROL; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; STATISTICAL SIGNIFICANCE; URINE VOLUME; VASOCONSTRICTION;

ADULT; ANTIBODIES, MONOCLONAL; CREATININE; CYCLOSPORINE; DOPAMINE; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; FEMALE; FENOLDOPAM; FUROSEMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LIVER TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECOMBINANT FUSION PROTEINS;

EID: 4544332835     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20145     Document Type: Article

References (32)

1. Niessen AR. Acute renal failure: definition and pathogenesis. Kidney Int 1998;53:S7-S10.
2. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, outcomes and hospital resource utilization. Ann Intern Med 1998;128:194-203.
3. Gonwa TA, Gavaler JS, Schade RR, Jennings LS, Golstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995;59:361-365.
4. Brown SR Jr, Lombardero M, Lake JR. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996;62:1788-1793.
5. Gainza FJ, Valdivieso A, Quintinilla N, Erratzi M, Gastatca M, Campo I, et al. Evaluation of acute renal failure in the liver transplantation perioperative period: incidence and impact. Transpl Int 2002;34:250-251.
6. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35:1179-1185.
7. Driscoll D, Pinson C, Bistrian B. Potential protective effects of furosemide against early cyclosporine-induced renal injury in hepatic transplant recipients. Transplant Proc 1989;21:3549-3550.
8. Polson RJ, Park GR, Lindop MJ, Farman J, Calne R, Williams R. The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia 1987;42:15-19.
9. Tan LB, Smith SA, Littler WA, Murray RG. Haemodynamic and renal effects of dopexamine in low output heart renal failure [Abstract]. Br Heart J 1987;57:81.
10. Durand F, Aschehoug J, Sauvenet A, Bernuau J, Benhamou JP, Erlinger S, Belghiti J. Preservation of renal perfusion and postoperative renal function by side-to-side cavo-caval anastomosis in liver transplant recipients. Transpl Int 1995;8:407-410.
11. Bilbao M, Charco R, Balsells J, Lazaro JL, Hidalgo E, Liopart L, et al. Risk factors for acute renal failure after liver transplantation. Clin Transpl 1998;12:123-129.
12. Fraley DS, Burr R, Bernardini J, Angus D, Kramer DJ, Johnson J. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int 1998;54:518-524.
13. McDonald M, Perkins JD, Ralph D, Carithers RL. Postoperative care: immediate. In: Maddrey WC, Sorrel MF, eds. Transplantation of the liver, 2nd ed. Norwalk: Appleton & Lange, 1996:171-206.
14. Martinelli I, Moia M, Gridelli B, Panzeri D, Langer M, Mannucci PM. Prognostic value of the activated partial thromboplastin time after orthotopic liver transplantation. A prospective study. Int J Clin Lab Res 1994;24:220-222.
15. Halpenny M, Markos F, Snow H, Duggan P, Gaffney E, O'Connel D, Shorten G. Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs. Crit Care Med 2001; 29:855-860.
16. Eckardt K. Renal failure in liver disease. Intensive Care Med 1999;25:5-14.
17. Driscoll DF, Pinson CW, Jenkins RL, Bistrian BR. Potential protective effects of furosemide against early renal injury in liver transplant patients receiving cyclosporine-A. Crit Care Med 1989;17:1341-1342.
18. Dishart MK, Kellum JA. An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure. Drugs 2000;59:79-91.
19. Swygert TH, Roberts LC, Valeck TR, Brajtbord D, Brown MR, Gunning TC, et al. Effect of intraoperative low-dose dopamine on renal function in liver transplant recipients. Anesthesiology 1991;75:571-576.
20. Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med 2002;28:877-883.
21. Mathur VS, Swan SK, Lambrecht LJ, Anjum S, Fellmann,J, McGuire D, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999;27:1832-1837.
22. Sladen RN. Will this magic bullet fly true? Crit Care Med 2001; 29:904-913.
23. Aurora RN, Milite F, Carlton G. Preventing renal failure in critically ill patients. Crit Care Med 1999;27:2044-2045.
24. Della Rocca G, Costa MG, Pietropaoli P. Fenoldopam in major surgery. Minerva Anestesiol 2001;67(Suppl 1):57-61.
25. Halpenny M, Rushe C, Breen P, Cunningham AJ, Boucher-Hayes D, Shorten GD. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 2002;19:32-39.
26. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high risk patients. Catheter Cardiovasc Interv 2001;53:341-345.
27. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Baiwa TK. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-283.
28. Carton EG, Plevak DJ, Kranner PW, Rettke SR, Geiger HJ, Coursin DB. Perioperative care of the liver transplant patient: part 2. Anesth Analg 1994;78:382-399.
29. Biancofiore G, Bindi ML, Romanelli AM, Bisà M, Boldrini A, Consani G, et al. Intra-abdominal pressure monitoring: a prospective study. Intensive Care Med 2003;29:30-36.
30. Brooks DP, Drutz DJ, Ruffolo RR Jr. Prevention and complete reversal of cyclosporine A induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam. J Pharmacol Exp Ther 1999;204:375-379.
31. Jorkasky DK, Audet P, Shusterman N, Ilson B, Dafoe D, Hedrik D, Stote RM. Fenoldopam reverses cyclosporine induced renal vasoconstriction in kidney transplant patients. Am J Kidney Dis 1992;19:567-572.
32. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorder: implications for liver transplantation. Part 1. Liver Transpl 2001,8:91-109.